Speaker Profile
Ph.D., Professor and Director, Institute for Precision Medicine, U. of Pittsburgh
Biography
Dr. Adrian Lee is the Pittsburgh Foundation Chair and Director of theInstitute for Precision Medicine (IPM), a joint effort by UPMC and theUniversity of Pittsburgh to move biomedical research into personalizedwell-being and clinical care. He is also Professor of Pharmacology Chemical Biology and Human Genetics at UPMC Hillman Cancer Center. Dr. Leereceived B.Sc. and Ph.D. degrees in England, and came to San Antonio, Texasfor his postdoctoral studies. He was subsequently recruited to BaylorCollege of Medicine and to the University of Pittsburgh in 2010. The goalof Dr. Lees research laboratory is to translate basic cell and molecularresearch findings into the understanding and treatment of breast cancer. DrLee has published over 180 peer reviewed research articles. His laboratoryis supported by funding from the NIH, Department of Defense, Susan G. Komenfor the Cure, Breast Cancer Research Foundation, and other sources.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Adrian Lee, UPMC
PMWC Award Ceremony
• Dennis J. Slamon, UCLA
• Arul M. Chinnaiyan, University of Michigan
Keynote
• Dennis J. Slamon, UCLA
Keynote: From Cancer Drivers to Clinical Decisions: Transforming Tumor Genomics into Therapy Guidance
• Arul M. Chinnaiyan, University of Michigan
Serial ctDNA-Guided Therapy Switching (SERENA-6 & Beyond)
• Chair: Adrian Lee, UPMC
• Pedram Razavi, MSK
• Minetta Liu, Natera
• Christian Rolfo, Ohio State
Neoadjuvant to Adjuvant MRD: How Early Is Early Enough?
• Chair: Angela DeMichele, UPenn
• Halla Nimeiri, Tempus
• Aparna Parikh, Harvard
• Minetta Liu, Natera
• Christopher Lieu, University of Colorado
Rapid MRD to Treatment Decisions: Standardized ctDNA at Scale
• Chair: Luca Quagliata, Thermo Fisher
• Christian Rolfo, Ohio State
Multi-Omics Monitoring Beyond Variants: Methylation, Fragmentomics, EV/ctRNA
• David T. Miyamoto, Massachusetts General Hospital
• Maximilian Diehn, Stanford
• Daniel De Carvalho, University of Toronto
• Arul M. Chinnaiyan, University of Michigan
From Detection to Direction: Whole-Genome MRD for Therapy Guidance at Scale
• Phil Febbo, Veracyte
From Validation to Payment: Coverage Pathways That Work
• Chair: Mark Stewart, Friends of Cancer Research
• Hilary Gee Goeckner, American Cancer Society (ACS)
• Sally Werner, Cancer Support Community
• Gabriel A. Bien-Willner, Palmetto GBA
